The gene therapy company expects Phase I/II biomarker and preliminary clinical data for TSHA-101 in GM2 gangliosidosis in the second half of 2021 ...
https://www.google.com/url?rct=j&sa=t&url=https://www.thepharmaletter.com/in-brief/brief-taysha-offers-healthy-progress-update&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNFUjeB_9iVDip1KrlDYY83yd-Ph2A
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.